AI Article Synopsis
- - The study utilized matching-adjusted indirect comparisons (MAIC) to evaluate the effectiveness of bimekizumab versus guselkumab in treating patients with psoriatic arthritis who had not previously received biologic therapy or had inadequate responses to TNF inhibitors.
- - Data were collected from systematic literature reviews and multiple clinical trials, allowing for comparisons of treatment outcomes based on individual patient data and summary data from various studies.
- - Results showed that bimekizumab was significantly more effective than guselkumab in achieving higher rates of improvement in American College of Rheumatology scores and minimal disease activity in both treatment-naïve and TNFi-resistant patient groups.
Article Abstract
Introduction: Matching-adjusted indirect comparisons (MAIC) were used to assess the relative efficacy of bimekizumab 160 mg every 4 weeks (Q4W) compared to guselkumab 100 mg Q4W or every 8 weeks (Q8W) at 48/52 weeks in patients with psoriatic arthritis (PsA) who were biologic disease-modifying antirheumatic drug-naïve (bDMARD-naïve) or with previous inadequate response or intolerance to tumor necrosis factor inhibitors (TNFi-IR).
Methods: Relevant trials were identified as part of a systematic literature review. For patients who were bDMARD-naïve, individual patient data (IPD) from BE OPTIMAL (N = 431) was matched to summary data from DISCOVER-2 (Q4W, n = 245; Q8W, n = 248). For patients who were TNFi-IR, IPD from BE COMPLETE (n = 267) and summary data from COSMOS (Q8W, N = 189). Trial populations were re-weighted using propensity scores. Unanchored comparisons of recalculated bimekizumab and guselkumab 48- or 52-week non-responder imputation outcomes for 20/50/70% improvement in American College of Rheumatology score (ACR20/50/70) and minimal disease activity (MDA) index were analyzed.
Results: In patients who were bDMARD-naïve, bimekizumab was associated with a greater likelihood of ACR50 (odds ratio [95% confidence interval] 1.62 [1.07, 2.44]; p = 0.021), ACR70 (2.20 [1.43, 3.38]; p < 0.001), and MDA (1.82 [1.20, 2.76]; p = 0.005) compared to guselkumab Q4W at week 52. Bimekizumab also had a greater likelihood of ACR70 response (2.08 [1.34, 3.22]; p = 0.001) and MDA (2.07 [1.35, 3.17]; p < 0.001) compared to guselkumab Q8W at week 52. In patients who were TNFi-IR, bimekizumab had a greater likelihood in achieving all evaluated outcomes compared to guselkumab Q8W at week 48/52 (ACR20, 1.77 [1.15, 2.72]; p = 0.010; ACR50, 1.56 [1.03, 2.36]; p = 0.037; ACR70, 1.66 [1.05, 2.61]; p = 0.028; and MDA, 1.95 [1.27, 3.02]; p = 0.003).
Conclusions: According to MAICs, bimekizumab demonstrated greater or comparable efficacy on ACR50/70 and MDA outcomes than guselkumab in patients with PsA who were bDMARD-naïve and TNFi-IR at week 48/52. Bimekizumab had a more favorable likelihood than guselkumab in achieving more stringent treatment outcomes.
Trial Registrations: NCT03895203, NCT03896581, NCT04009499, NCT03158285, NCT03796858.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11111623 | PMC |
| http://dx.doi.org/10.1007/s40744-024-00659-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Obesity is a metabolic disease that is marked by excessive fat accumulation and is objectively defined as a body mass index (BMI) ≥30 kg/m2. Obesity is associated with several other comorbidities, including psoriasis, which is a chronic autoimmune skin disease. Adipocytes produce pro-inflammatory signaling molecules, namely adipokines and classic cytokines, that drive increased inflammation axnd may contribute to the pro-inflammatory pathways driving psoriasis disease pathogenesis.
View Article and Find Full Text PDFBiologics Use for Psoriasis during Pregnancy and Its Related Adverse Outcomes in Pregnant Women and Newborns: Findings from WHO Pharmacovigilance Study.
Int Arch Allergy Immunol
December 2024
Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, Republic of Korea.
Article Synopsis
- The study investigates the safety of various biologics used for psoriasis during pregnancy, highlighting that data on risks is lacking outside of TNF-α inhibitors.
- Using the WHO global pharmacovigilance database, researchers analyzed over 6,500 reports of pregnancy-related adverse outcomes and compared them among different biologics.
- The findings indicate that most biologics have a lower frequency of adverse pregnancy-related outcomes compared to TNF-α inhibitors, except for brodalumab, while risankizumab showed a higher incidence of abortion and stillbirth.
Long-Term Efficacy and Safety of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: Updated Systematic Literature Review and Network Meta-analysis.
Dermatol Ther (Heidelb)
November 2024
Division of Dermatology, University of California Los Angeles (UCLA), Los Angeles, CA, USA.
Article Synopsis
- Biologic treatments have shown promise in achieving complete skin clearance for moderate to severe plaque psoriasis, with bimekizumab demonstrating superior efficacy compared to other treatments like secukinumab, adalimumab, and ustekinumab in clinical trials.
- A systematic literature review and network meta-analysis evaluated 19 randomized controlled trials to compare the efficacy and safety of bimekizumab against other biologic therapies over one year, focusing on improvements in the Psoriasis Area and Severity Index (PASI).
- The results indicated that bimekizumab 320 mg given every 4 weeks, then every 8 weeks, was more effective in achieving complete skin clearance compared to most other biologics, particularly highlighting the efficacy
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!